{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:16:48Z","timestamp":1792289808167,"version":"4.4.0"},"reference-count":176,"publisher":"American Diabetes Association","issue":"Supplement_1","license":[{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:p>The American Diabetes Association (ADA) \u201cStandards of Medical Care in Diabetes\u201d includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org\/SOC.<\/jats:p>","DOI":"10.2337\/dc19-s010","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:19:21Z","timestamp":1545092361000},"page":"S103-S123","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":382,"title":["10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetes\u20142019<\/i>"],"prefix":"10.2337","volume":"42","author":[{"name":"American Diabetes Association","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"key":"2022031221221331600_B1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B2","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMsa1213829","article-title":"Achievement of goals in U.S. diabetes care, 1999\u20132010","volume":"368","author":"Ali","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2337\/dc07-9917","article-title":"Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"30","author":"Buse","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"2022031221221331600_B6","article-title":"Incidence of hospitalisation for heart failure and case-fatality among 3.25 million people with and without diabetes","author":"McAllister","journal-title":"Circulation"},{"key":"2022031221221331600_B7","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","article-title":"Heart failure with preserved ejection fraction: from mechanisms to therapies","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"2022031221221331600_B8","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/eurheartj\/ehx511","article-title":"Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME\u00ae trial","volume":"39","author":"Fitchett","year":"2018","journal-title":"Eur Heart J"},{"key":"2022031221221331600_B11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(14)61212-5","article-title":"Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data","volume":"384","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2014","journal-title":"Lancet"},{"key":"2022031221221331600_B12","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022031221221331600_B13","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2014.2630","article-title":"Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations","volume":"311","author":"Muntner","year":"2014","journal-title":"JAMA"},{"key":"2022031221221331600_B14","first-page":"598","article-title":"Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort","volume":"38","author":"DeFilippis","year":"2017","journal-title":"Eur Heart J"},{"key":"2022031221221331600_B15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022031221221331600_B16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.115.019861","article-title":"atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"2022031221221331600_B17","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2337\/dci17-0026","article-title":"Diabetes and hypertension: a position statement by the American Diabetes Association","volume":"40","author":"de Boer","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B18","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1001\/archinte.161.18.2205","article-title":"Is \u201cisolated home\u201d hypertension as opposed to \u201cisolated office\u201d hypertension a sign of greater cardiovascular risk?","volume":"161","author":"Bobrie","year":"2001","journal-title":"Arch Intern Med"},{"key":"2022031221221331600_B19","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000160923.04524.5B","article-title":"Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study","volume":"111","author":"Sega","year":"2005","journal-title":"Circulation"},{"key":"2022031221221331600_B20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/HJH.0b013e32835ca8dd","article-title":"Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies","volume":"31","author":"Omboni","year":"2013","journal-title":"J Hypertens"},{"key":"2022031221221331600_B21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"key":"2022031221221331600_B22","first-page":"CD008277","article-title":"Blood pressure targets for hypertension in people with diabetes mellitus","volume":"10","author":"Arguedas","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031221221331600_B23","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"2022031221221331600_B24","doi-asserted-by":"crossref","first-page":"i717","DOI":"10.1136\/bmj.i717","article-title":"Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses","volume":"352","author":"Brunstr\u00f6m","year":"2016","journal-title":"BMJ"},{"key":"2022031221221331600_B25","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/CIRCULATIONAHA.110.016337","article-title":"Blood pressure targets in subjects with type 2 diabetes mellitus\/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials","volume":"123","author":"Bangalore","year":"2011","journal-title":"Circulation"},{"key":"2022031221221331600_B26","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","article-title":"Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials","volume":"35","author":"Thomopoulos","year":"2017","journal-title":"J Hypertens"},{"key":"2022031221221331600_B27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"2022031221221331600_B28","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"2022031221221331600_B30","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/CIRCULATIONAHA.116.022536","article-title":"The implications of blood pressure measurement methods on treatment targets for blood pressure","volume":"134","author":"Bakris","year":"2016","journal-title":"Circulation"},{"key":"2022031221221331600_B31","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2337\/dc13-2334","article-title":"Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial","volume":"37","author":"Margolis","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B32","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2337\/dc17-1366","article-title":"Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP [published correction appears in Diabetes Care 2018;41:2048]","volume":"40","author":"Buckley","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B33","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.2337\/dc17-1722","article-title":"Intensive blood pressure lowering in patients with and patients without type 2 diabetes: a pooled analysis from two randomized trials","volume":"41","author":"Brouwer","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B34","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2337\/dci17-0063","article-title":"Reevaluating the evidence for blood pressure targets in type 2 Diabetes","volume":"41","author":"Lamprea-Montealegre","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B35","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.2018.0642","article-title":"individualizing blood pressure targets for people with diabetes and hypertension: comparing the ADA and the ACC\/AHA recommendations","volume":"319","author":"de Boer","year":"2018","journal-title":"JAMA"},{"key":"2022031221221331600_B36","doi-asserted-by":"crossref","first-page":"e1002410","DOI":"10.1371\/journal.pmed.1002410","article-title":"Benefit and harm of intensive blood pressure treatment: derivation and validation of risk models using data from the SPRINT and ACCORD trials","volume":"14","author":"Basu","year":"2017","journal-title":"PLoS Med"},{"key":"2022031221221331600_B37","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2018.01.074","article-title":"Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension","volume":"71","author":"Phillips","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022031221221331600_B38","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022031221221331600_B39","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2213-8587(18)30099-8","article-title":"Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials","volume":"6","author":"Beddhu","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031221221331600_B41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/jgs.15236","article-title":"Syncope, hypotension, and falls in the treatment of hypertension: results from the randomized clinical Systolic Blood Pressure Intervention Trial","volume":"66","author":"Sink","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"2022031221221331600_B42","first-page":"1122","article-title":"Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists\u2019 Task Force on Hypertension in Pregnancy","volume":"122","author":"American College of Obstetricians and Gynecologists\u2019","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2022031221221331600_B43","doi-asserted-by":"crossref","unstructured":"Abalos\u2008E, Duley\u2008L, Steyn\u2008DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev\u20082014;2:CD002252","DOI":"10.1002\/14651858.CD002252.pub3"},{"key":"2022031221221331600_B44","first-page":"44","article-title":"Use of diuretics during pregnancy","volume":"55","author":"Al-Balas","year":"2009","journal-title":"Can Fam Physician"},{"key":"2022031221221331600_B45","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/bmj.323.7323.1213","article-title":"Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study","volume":"323","author":"Irgens","year":"2001","journal-title":"BMJ"},{"key":"2022031221221331600_B46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet","volume":"344","author":"Sacks","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"2022031221221331600_B48","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1524-6175.2002.2041.x","article-title":"Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches","volume":"5","author":"Bakris","year":"2003","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2022031221221331600_B49","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/HYPERTENSIONAHA.108.123455","article-title":"A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial","volume":"53","author":"Feldman","year":"2009","journal-title":"Hypertension"},{"key":"2022031221221331600_B50","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jama.2018.10359","article-title":"Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial","volume":"320","author":"Webster","year":"2018","journal-title":"JAMA"},{"key":"2022031221221331600_B51","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: a meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"Am J Med"},{"key":"2022031221221331600_B52","doi-asserted-by":"crossref","first-page":"e1001971","DOI":"10.1371\/journal.pmed.1001971","article-title":"Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses","volume":"13","author":"Catal\u00e1-L\u00f3pez","year":"2016","journal-title":"PLoS Med"},{"key":"2022031221221331600_B53","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"key":"2022031221221331600_B54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1524-6175.2004.03216.x","article-title":"Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study","volume":"6","author":"Barzilay","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2022031221221331600_B55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","article-title":"Cardiovascular events during differing hypertension therapies in patients with diabetes","volume":"56","author":"Weber","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022031221221331600_B56","doi-asserted-by":"crossref","first-page":"i438","DOI":"10.1136\/bmj.i438","article-title":"Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials","volume":"352","author":"Bangalore","year":"2016","journal-title":"BMJ"},{"key":"2022031221221331600_B57","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"key":"2022031221221331600_B58","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B59","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B60","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials","volume":"346","author":"Makani","year":"2013","journal-title":"BMJ"},{"key":"2022031221221331600_B61","first-page":"CD004184","article-title":"Evening versus morning dosing regimen drug therapy for hypertension","volume":"10","author":"Zhao","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031221221331600_B62","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2337\/dc11-0297","article-title":"Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes","volume":"34","author":"Hermida","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B63","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijcard.2017.07.035","article-title":"Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system","volume":"245","author":"Nilsson","year":"2017","journal-title":"Int J Cardiol"},{"key":"2022031221221331600_B64","doi-asserted-by":"crossref","first-page":"e005428","DOI":"10.1161\/JAHA.116.005428","article-title":"Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project","volume":"6","author":"Bandak","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2022031221221331600_B65","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2215\/CJN.06290616","article-title":"The relation of serum potassium concentration with cardiovascular events and mortality in community-living individuals","volume":"12","author":"Hughes-Austin","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031221221331600_B66","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.ajkd.2015.02.338","article-title":"A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury","volume":"66","author":"James","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2022031221221331600_B67","doi-asserted-by":"crossref","first-page":"F583","DOI":"10.1152\/ajprenal.00246.2015","article-title":"Renal denervation for the treatment of resistant hypertension: review and clinical perspective","volume":"309","author":"Iliescu","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031221221331600_B68","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2022031221221331600_B69","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2022031221221331600_B70","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"2022031221221331600_B71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000334161","article-title":"Mineralocorticoid receptor blockade in chronic kidney disease","volume":"33","author":"Bomback","year":"2012","journal-title":"Blood Purif"},{"key":"2022031221221331600_B72","first-page":"S102","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022031221221331600_B73","doi-asserted-by":"crossref","unstructured":"Estruch\u2008R, Ros\u2008E, Salas-Salvad\u00f3\u2008J, et al.; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med\u20082018;378:e34","DOI":"10.1056\/NEJMoa1800389"},{"key":"2022031221221331600_B74","first-page":"S76","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume-title":"Circulation","author":"Eckel","year":"2013"},{"key":"2022031221221331600_B75","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction","volume":"291","author":"Chasman","year":"2004","journal-title":"JAMA"},{"key":"2022031221221331600_B76","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1185\/03007995.2012.657302","article-title":"Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study","volume":"28","author":"Meek","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"2022031221221331600_B77","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"2022031221221331600_B78","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"2022031221221331600_B79","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)","volume":"20","author":"Py\u014fr\u00e4l\u00e4","year":"1997","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B80","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"2022031221221331600_B81","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","article-title":"Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial","volume":"98","author":"Goldberg","year":"1998","journal-title":"Circulation"},{"key":"2022031221221331600_B82","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2337\/dc05-2465","article-title":"Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study","volume":"29","author":"Shepherd","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B83","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2337\/diacare.28.5.1151","article-title":"Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial\u2013lipid-lowering arm (ASCOT-LLA)","volume":"28","author":"Sever","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B84","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B85","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"2022031221221331600_B86","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"2022031221221331600_B87","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031221221331600_B88","article-title":"Risk of incident diabetes among patients treated with statins: population based study [published correction appears in BMJ 2013;347:f4356]","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ"},{"key":"2022031221221331600_B89","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"2022031221221331600_B90","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B91","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/CIR.0000000000000034","article-title":"Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association","volume":"130","author":"de Ferranti","year":"2014","journal-title":"Circulation"},{"key":"2022031221221331600_B92","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B93","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B94","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"2022031221221331600_B95","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2022031221221331600_B96","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"key":"2022031221221331600_B97","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031221221331600_B98","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221221331600_B99","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jama.298.7.786","article-title":"High-density lipoprotein as a therapeutic target: a systematic review","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA"},{"key":"2022031221221331600_B100","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"2022031221221331600_B101","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin","volume":"95","author":"Jones","year":"2005","journal-title":"Am J Cardiol"},{"key":"2022031221221331600_B102","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B103","unstructured":"Kowa Research Institute, Inc\n          . Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03071692. NLM Identifier: NCT03071692. Accessed 8 October 2018"},{"key":"2022031221221331600_B104","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B106","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2337\/dc09-0738","article-title":"Statin therapy and risk of developing type 2 diabetes: a meta-analysis","volume":"32","author":"Rajpathak","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B107","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"2022031221221331600_B108","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"2022031221221331600_B109","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: perception vs. the evidence \u2013 focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Eur Heart J"},{"key":"2022031221221331600_B110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"2022031221221331600_B111","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"2022031221221331600_B112","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00415-009-5271-7","article-title":"Pravastatin and cognitive function in the elderly. Results of the PROSPER study","volume":"257","author":"Trompet","year":"2010","journal-title":"J Neurol"},{"key":"2022031221221331600_B113","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B114","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B115","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","article-title":"Statins and cognitive function: a systematic review","volume":"159","author":"Richardson","year":"2013","journal-title":"Ann Intern Med"},{"key":"2022031221221331600_B116","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"2022031221221331600_B117","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"2022031221221331600_B118","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"2022031221221331600_B119","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.diabres.2009.09.029","article-title":"Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis","volume":"87","author":"Zhang","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031221221331600_B120","doi-asserted-by":"crossref","first-page":"b4531","DOI":"10.1136\/bmj.b4531","article-title":"Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials","volume":"339","author":"De Berardis","year":"2009","journal-title":"BMJ"},{"key":"2022031221221331600_B121","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"ASCEND Study Collaborative Group","year":"2018","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B122","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"2022031221221331600_B123","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B124","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-144-5-200603070-00007","article-title":"Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis","volume":"144","author":"Pignone","year":"2006","journal-title":"Ann Intern Med"},{"key":"2022031221221331600_B125","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2337\/dc10-0555","article-title":"Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation","volume":"33","author":"Pignone","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B126","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S2213-8587(14)70248-7","article-title":"Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis","volume":"3","author":"Huxley","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031221221331600_B127","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1007\/s00125-014-3260-6","article-title":"Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events","volume":"57","author":"Peters","year":"2014","journal-title":"Diabetologia"},{"key":"2022031221221331600_B128","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2337\/dc13-1755","article-title":"Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults","volume":"37","author":"Kalyani","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B129","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/S0140-6736(14)60040-4","article-title":"Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes","volume":"383","author":"Peters","year":"2014","journal-title":"Lancet"},{"key":"2022031221221331600_B130","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.amjcard.2015.12.023","article-title":"Value of coronary computed tomography angiography in tailoring aspirin therapy for primary prevention of atherosclerotic events in patients at high risk with diabetes mellitus","volume":"117","author":"Dimitriu-Leen","year":"2016","journal-title":"Am J Cardiol"},{"key":"2022031221221331600_B131","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jama.2016.8362","article-title":"Low-dose aspirin in the primary prevention of cardiovascular disease: shared decision making in clinical practice","volume":"316","author":"Mora","year":"2016","journal-title":"JAMA"},{"key":"2022031221221331600_B132","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1001\/jama.297.18.2018","article-title":"Aspirin dose for the prevention of cardiovascular disease: a systematic review","volume":"297","author":"Campbell","year":"2007","journal-title":"JAMA"},{"key":"2022031221221331600_B133","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B134","doi-asserted-by":"crossref","first-page":"e0126767","DOI":"10.1371\/journal.pone.0126767","article-title":"Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease","volume":"10","author":"Larsen","year":"2015","journal-title":"PLoS One"},{"key":"2022031221221331600_B135","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2337\/db15-0936","article-title":"In vivo platelet activation and aspirin responsiveness in type 1 diabetes","volume":"65","author":"Zaccardi","year":"2016","journal-title":"Diabetes"},{"key":"2022031221221331600_B136","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/dme.12828","article-title":"Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with type 2 diabetes","volume":"33","author":"Bethel","year":"2016","journal-title":"Diabet Med"},{"key":"2022031221221331600_B137","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","article-title":"Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials","volume":"392","author":"Rothwell","year":"2018","journal-title":"Lancet"},{"key":"2022031221221331600_B138","doi-asserted-by":"crossref","first-page":"e637S","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published correction appears in","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"key":"2022031221221331600_B139","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022031221221331600_B140","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.2337\/dc07-9927","article-title":"Screening for coronary artery disease in patients with diabetes","volume":"30","author":"Bax","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B141","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B142","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A randomized trial of therapies for type 2 diabetes and coronary artery disease","volume":"360","author":"BARI 2D Study Group","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B143","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.2337\/dc07-1250","article-title":"Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study","volume":"30","author":"Wackers","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B144","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/eurheartj\/ehn279","article-title":"Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study","volume":"29","author":"Elkeles","year":"2008","journal-title":"Eur Heart J"},{"key":"2022031221221331600_B145","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.jacc.2003.09.068","article-title":"Prognostic value of coronary artery calcium screening in subjects with and without diabetes","volume":"43","author":"Raggi","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2022031221221331600_B146","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/eurheartj\/ehi808","article-title":"Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy","volume":"27","author":"Anand","year":"2006","journal-title":"Eur Heart J"},{"key":"2022031221221331600_B147","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.2009.476","article-title":"Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial","volume":"301","author":"Young","year":"2009","journal-title":"JAMA"},{"key":"2022031221221331600_B148","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2337\/diacare.27.8.1954","article-title":"Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study","volume":"27","author":"Wackers","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B149","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jacc.2005.10.008","article-title":"Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus","volume":"47","author":"Scognamiglio","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2022031221221331600_B150","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.2337\/dc09-2104","article-title":"Prognostic value of coronary computed tomographic angiography in diabetic patients without known coronary artery disease","volume":"33","author":"Hadamitzky","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031221221331600_B151","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.amjcard.2009.05.026","article-title":"Assessment of subclinical coronary atherosclerosis in asymptomatic patients with type 2 diabetes mellitus with single photon emission computed tomography and coronary computed tomography angiography","volume":"104","author":"Choi","year":"2009","journal-title":"Am J Cardiol"},{"key":"2022031221221331600_B152","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamacardio.2017.4191","article-title":"Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic Study of Atherosclerosis","volume":"2","author":"Malik","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2022031221221331600_B153","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B154","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B155","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators","year":"2008","journal-title":"Lancet"},{"key":"2022031221221331600_B156","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/157340312801215764","article-title":"Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it \u201cok\u201d to discontinue?","volume":"8","author":"Kezerashvili","year":"2012","journal-title":"Curr Cardiol Rev"},{"key":"2022031221221331600_B157","unstructured":"U.S. Food and Drug Administration\n          . Guidance for industry. Diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. Silver Spring, MD, 2008. Available from http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071627.pdf). Accessed 3 November 2017"},{"key":"2022031221221331600_B158","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.12829","article-title":"Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2022031221221331600_B159","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B160","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B161","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B162","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B163","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"2022031221221331600_B164","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: the Framingham study","volume":"34","author":"Kannel","year":"1974","journal-title":"Am J Cardiol"},{"key":"2022031221221331600_B165","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"2022031221221331600_B166","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","article-title":"Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA"},{"key":"2022031221221331600_B167","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"2022031221221331600_B168","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B169","unstructured":"U.S. Food and Drug Administration\n          . FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin [Internet], 2016. Available from http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm486096.htm. Accessed 24 September 2018"},{"key":"2022031221221331600_B170","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"2022031221221331600_B171","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B172","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/eurheartj\/ehx511","article-title":"Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial","volume":"39","author":"Fitchett","year":"2017","journal-title":"Eur Heart J"},{"key":"2022031221221331600_B173","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"2022031221221331600_B174","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","article-title":"Follow-up of blood-pressure lowering and glucose control in type 2 diabetes","volume":"371","author":"Zoungas","year":"2014","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B175","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031221221331600_B176","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dci17-0057","article-title":"Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors\u2019 Expert Forum","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/Supplement_1\/S103\/549652\/dc19s010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/Supplement_1\/S103\/549652\/dc19s010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T23:35:53Z","timestamp":1647128153000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/42\/Supplement_1\/S103\/30856\/10-Cardiovascular-Disease-and-Risk-Management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,7]]},"references-count":176,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2018,12,7]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc19-s010","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,7]]}}}